azacitidine and Anemia, Sideroblastic

azacitidine has been researched along with Anemia, Sideroblastic in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (33.33)	29.6817
2010's	2 (33.33)	24.3611
2020's	2 (33.33)	2.80

Authors

Authors	Studies
Chonabayashi, K; Inagaki, A; Kawabata, H; Morimoto, Y; Nagao, M; Nakanishi, K; Narita, M; Nishikawa, M; Okubo, C; Takaori-Kondo, A; Yamasaki-Morita, M; Yoshida, Y	1
Balleari, E; Campelo, MD; Fenaux, P; Germing, U; Götze, KS; Guerci-Bresler, A; Hamel, JF; Kelaidi, C; Komrokji, R; Kotsianidis, I; Park, S; Santini, V; Sanz, GF; Sekeres, MA; Stamatoullas, A; Steensma, D; Thépot, S; Toma, A	1
Hanamoto, H; Ishikawa, J; Kawata, S; Maeda, Y; Matsuda, M; Matsumura, I; Morita, Y; Shibayama, H; Tsubaki, K; Urase, F; Yamaguchi, T	1
Kim, J; Kim, YR; Lee, KA	1
Steensma, DP; Tefferi, A	1
Andre, M; Bosly, A; Ferrant, A; Kunzmann, R; Lübbert, M; Ravoet, C; Verhoef, G; Wijermans, P	1

Reviews

1 review(s) available for azacitidine and Anemia, Sideroblastic

Article	Year
Risk-based management of myelodysplastic syndrome. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1 Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles	2007

Article

Year

Risk-based management of myelodysplastic syndrome.

Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:1

Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles

2007

Trials

1 trial(s) available for azacitidine and Anemia, Sideroblastic

Article	Year
Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial. Cancer science, 2018, Volume: 109, Issue:10 Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Male; Middle Aged; Prospective Studies; Thrombocytopenia; Treatment Outcome	2018

Article

Year

Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial.

Cancer science, 2018, Volume: 109, Issue:10

Topics: Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Blood Component Transfusion; Drug Administration Schedule; Feasibility Studies; Febrile Neutropenia; Female; Humans; Japan; Male; Middle Aged; Prospective Studies; Thrombocytopenia; Treatment Outcome

2018

Other Studies

4 other study(ies) available for azacitidine and Anemia, Sideroblastic

Article	Year
Azacitidine is a potential therapeutic drug for pyridoxine-refractory female X-linked sideroblastic anemia. Blood advances, 2022, 02-22, Volume: 6, Issue:4 Topics: 5-Aminolevulinate Synthetase; Aminolevulinic Acid; Anemia, Sideroblastic; Azacitidine; Female; Genetic Diseases, X-Linked; Humans; Pharmaceutical Preparations; Pyridoxine	2022
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents. Leukemia research, 2020, Volume: 99 Topics: Activin Receptors, Type II; Aged; Anemia, Sideroblastic; Azacitidine; Disease Progression; Erythrocyte Transfusion; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Lenalidomide; Male; Proportional Hazards Models; Recombinant Fusion Proteins; Salvage Therapy; Treatment Failure	2020
Refractory anemia with ring sideroblasts associated with marked thrombocytosis harboring cytogenetic abnormality dup(2)(p15p22) treated with decitabine. Leukemia & lymphoma, 2012, Volume: 53, Issue:11 Topics: Anemia, Refractory; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Duplication; Chromosomes, Human, Pair 2; Decitabine; Humans; Male; Middle Aged; Thrombocytosis	2012
Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine. British journal of haematology, 2001, Volume: 114, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Aberrations; Chromosome Disorders; Decitabine; Drug Administration Schedule; Female; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Risk; Survival Rate	2001